Live Quote · OTCXSNXHealthcare· Biotechnology

NovAccess Global Inc.

$0.00 0.00%(+$0.00)
TickerSpark Score
39/100
Weak
80
Valuation
40
Profitability
15
Growth
32
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XSNX research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$0.05
Company Overviewnovaccessglobal.com

About the company

Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells.

CEO
Dwain K. Morris-Irvin
IPO
1998
Employees
3
HQ
Chesterland, OH, US

Price Chart

-66.67% · this period
$0.00$0.00$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$6.17K
P/E
-0.00
P/S
0.00
P/B
-0.00
EV/EBITDA
-2.11
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
76.60%
ROIC
-0.01%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-4,769,187 · -177.93%
EPS
$-0.23 · -130.00%
Op Income
$-2,466,760
FCF YoY
30.86%
Performance & Tape
52W High
$0.05
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
2.80
Avg Volume
633

Get TickerSpark's AI analysis on XSNX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 17, 24Sumner Davidother0
May 31, 24CASSARINI JOHNother0
Mar 13, 23LAIRD NEIL Jother428,571
Mar 13, 23CASSARINI JOHNother857,143
Mar 13, 23Anderson Jason Michaelother857,143
Mar 18, 22Anderson Jason Michaelother0
Mar 14, 22CASSARINI JOHNother0
Mar 14, 22Martin Daniel G.other1,502,670
Mar 14, 22Martin Daniel G.other25,000
Mar 14, 22Martin Daniel G.other25,000
Coverage · XSNX

Our XSNX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on XSNX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate XSNX report →
Internal Compare

Similar companies

Peers in the same neighborhood.